期刊
VIRUSES-BASEL
卷 9, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/v9050095
关键词
HBV; liver immunity; innate immunity; viral escape; immune therapeutic concepts
类别
资金
- French National Institute of Health and Medical Research (INSERM)
- French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
- CSS4
- Foundation for Innovation in Infectiology (FINOVI)
- Foundation for Medical Research (FRM) [DEQ20110421327]
- Hoffmann-La-Roche (pRED, Basel, Switzerland)
- Gilead Sciences (Foster city, CA, USA)
- Novira Therapeutics (Doylestown, PA, USA)
- ANRS
- DEVweCAN LABEX of the Universite de Lyon within the program Investissements d'Avenir [ANR-10-LABX-0061, ANR-11-IDEX-0007]
The hepatitis B virus (HBV) infects hepatocytes, which are the main cell type composing a human liver. However, the liver is enriched with immune cells, particularly innate cells (e.g., myeloid cells, natural killer and natural killer T-cells (NK/NKT), dendritic cells (DCs)), in resting condition. Hence, the study of the interaction between HBV and innate immune cells is instrumental to: (1) better understand the conditions of establishment and maintenance of HBV infections in this secondary lymphoid organ; (2) define the role of these innate immune cells in treatment failure and pathogenesis; and (3) design novel immune-therapeutic concepts based on the activation/restoration of innate cell functions and/or innate effectors. This review will summarize and discuss the current knowledge we have on this interplay between HBV and liver innate immunity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据